Study of Baricitinib Treatment for Adults with Moderate to Severe Traumatic Brain Injury Causing Intracerebral Hemorrhage or Contusions

What this Trial Is About

Researchers are evaluating the effects of baricitinib on people with moderate to severe traumatic intracerebral hemorrhage or contusions. This is a multicenter randomized control trial involving participants who have a radiological diagnosis of traumatic brain injury with an initial Glasgow Coma Scale GCS score between 5 and 12. The study aims to compare baricitinib combined with standard treatment to standard treatment alone to see if it improves patient outcomes. Participants will be divided into two groups. One group will receive the standard treatment according to current guidelines for traumatic brain injury. The other group will receive standard treatment plus baricitinib, given orally or through a nasogastric tube at a dose of 4 mg daily for 14 consecutive days starting soon after injury. The trial includes a control group and an experimental group to assess the effects of baricitinib. During the study, participants will be monitored for clinical improvement up to 180 days after injury. Researchers will assess outcomes like mortality rates at various time points, coma severity, and Glasgow Outcome Scale scores. They will also measure serum inflammatory factors, brain edema volume, intracranial pressure, and incidence of pneumonia within the first days to weeks after injury. Participants will undergo CT scans and laboratory tests as part of the monitoring process. The study involves follow-up evaluations to track recovery and safety over several months.

Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions